StockNews.com upgraded shares of Compugen (NASDAQ:CGEN – Free Report) from a hold rating to a buy rating in a research note issued to investors on Thursday.
Separately, Truist Financial lowered their price target on Compugen from $5.00 to $4.00 and set a buy rating on the stock in a research report on Tuesday, May 21st.
Get Our Latest Stock Report on CGEN
Compugen Stock Performance
Compugen (NASDAQ:CGEN – Get Free Report) last announced its earnings results on Monday, May 20th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.02. The company had revenue of $2.56 million during the quarter, compared to the consensus estimate of $2.79 million. On average, equities research analysts predict that Compugen will post 0.05 EPS for the current year.
Institutional Investors Weigh In On Compugen
A hedge fund recently bought a new stake in Compugen stock. Heron Bay Capital Management bought a new position in Compugen Ltd. (NASDAQ:CGEN – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 12,547 shares of the biotechnology company’s stock, valued at approximately $32,000. 12.22% of the stock is currently owned by hedge funds and other institutional investors.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Featured Stories
- Five stocks we like better than Compugen
- What is a Low P/E Ratio and What Does it Tell Investors?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Financial Services Stocks Investing
- MarketBeat Week in Review – 6/24 – 6/28
- High Flyers: 3 Natural Gas Stocks for March 2022
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.